Dense deposit disease: new insights

Purpose of reviewDense deposit disease is a rare but devastating disease primarily affecting children. This review focuses on new information regarding the pathophysiology of dense deposit disease, its appearance histopathologically, its relationship to other diseases including macular degeneration and acquired partial lipodystrophy and potential new therapies. Recent findingsThe microscopic features of dense deposit disease have been separated into five patterns with only about 25% of patients showing membranoproliferative features. The subtle interplay between genetic changes in complement regulatory proteins and dysregulation of the alternative pathway of complement is now more evident. Haplotype mapping has shown at-risk phenotypes of complement factor H associated with the development of dense deposit disease. Treatment protocols are empiric and not very effective. New information on complement inhibitors and plasma exchange, however, has brought hope for new therapies in the near future. SummaryUnderstanding of the pathology and the pathophysiology of dense deposit disease has advanced rapidly in the last decade. New efforts in genetic mapping along with the development of novel inhibitors of the complement system will lead to improved care for patients afflicted with this uncommon condition.

[1]  M. Gubler,et al.  H deficiency in two brothers with atypical dense intramembranous deposit disease. , 1986, Kidney international.

[2]  Jones Db.  Membranoproliferative glomerulonephritis. One of many diesases , 1977 .

[3]  C. Swainson,et al.  Mesangiocapillary glomerulonephritis: A long‐term study of 40 cases , 1983, The Journal of pathology.

[4]  P. Gallé,et al.  Recurrence of an original glomerular lesion in three renal allografts. , 1971, Transplantation proceedings.

[5]  B. Antoine,et al.  The clinical course associated with dense deposits in the kidney basement membranes. , 1972, Kidney international.

[6]  B. Spiegelman,et al.  Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. , 1992, The Journal of biological chemistry.

[7]  W. Couser.  Recurrent glomerulonephritis in the renal allograft: an update of selected areas. , 2005, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[8]  N. Gretz,et al.  Outcome of idiopathic membranoproliferative glomerulonephritis in children , 1996 .

[9]  B. Antoine,et al.  [Nephropathies with dense deposits in the basal membranes. Evolutive and clinical analysis of 43 cases. Statistical comparison with other chronic glomerulopathies]. , 1971, Journal d'urologie et de nephrologie.

[10]  V. Pollak,et al.  LOBULAR GLOMERULONEPHRITIS AND MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A Clinical and Pathologic Study Based on Renal Biopsies , 1971, Medicine.

[11]  John D Lambris,et al.  Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. , 2004, Biochemical Society transactions.

[12]  M. Pangburn,et al.  Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. , 1996, Biochemical pharmacology.

[13]  R. Sibley,et al.  Dense intramembranous deposit disease: new pathologic features. , 1984, Kidney International.

[14]  H. Knoell,et al.  Structure-Function Studies of the Complement System , 2002 .

[15]  B. Spiegelman,et al.  Adipsin and an endogenous pathway of complement from adipose cells. , 1992, The Journal of biological chemistry.

[16]  A. J. Mcadams,et al.  The alternative pathway C3 convertase and glomerular deposits , 1999, Pediatric Nephrology.

[17]  P. Loirat,et al.  [Parietoproliferative glomerulonephritis--(P.P.G.N.). Histopathological study under optic and electron microscopy and with immunochemistry of 49 cases. Anatomo-clinical correlations]. , 1971, Pathologie-biologie.

[18]  B. Ault.  Factor H and the pathogenesis of renal diseases , 2000, Pediatric Nephrology.

[19]  E. Briganti,et al.  Risk of renal allograft loss from recurrent glomerulonephritis. , 2002, The New England journal of medicine.

[20]  M. A. Mandal,et al.  Complement factor H: spatial and temporal expression and localization in the eye. , 2006, Investigative ophthalmology & visual science.

[21]  M. Walport,et al.  Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Alpers,et al.  Pathogenic mechanisms in membranoproliferative glomerulonephritis , 2005, Current opinion in nephrology and hypertension.

[23]  G. Tsokos,et al.  On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. , 1992, Clinical immunology and immunopathology.

[24]  H. Lutz,et al.  Complement amplification revisited. , 2006, Molecular immunology.

[25]  D. Power,et al.  Familial incidence of C3 nephritic factor, partial lipodystrophy and membranoproliferative glomerulonephritis. , 1990, The Quarterly journal of medicine.

[26]  P. Gallé,et al.  [DENSE DEPOSITS WITHIN THE BASAL MEMBRANES OF THE KIDNEY. OPTICAL AND ELECTRON MICROSCOPIC STUDY]. , 1963, La Presse medicale.

[27]  N. Young,et al.  The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. , 2006, The New England journal of medicine.

[28]  S. Kaveri,et al.  Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. , 2006, International immunopharmacology.

[29]  I. Mackay,et al.  Autoimmune diseases. , 1981, Scientific American.

[30]  P. Mathieson,et al.  Lipodystrophy in MCGN type II: the clue to links between the adipocyte and the complement system. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  J. H. Jansen,et al.  Porcine membranoproliferative glomerulonephritis type II: an autosomal recessive deficiency of factor H , 1995, Veterinary Record.

[32]  J. Alexander,et al.  The simple design of complement factor H: Looks can be deceiving. , 2007, Molecular immunology.

[33]  J. Wetzels,et al.  Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  J. Floege.  Recurrent glomerulonephritis following renal transplantation: an update. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  M. A. Jackson,et al.  Hypocomplementaemia, C3 nephritic factor and type III mesangiocapillary glomerulonephritis progressing to systemic lupus erythematosus. , 1995, British journal of rheumatology.

[36]  A. Bird,et al.  [Pathogenesis of lesions in late age-related macular disease]. , 2004, Journal francais d'ophtalmologie.

[37]  R. T. Smith,et al.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  John D Lambris,et al.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. , 2005, Journal of the American Society of Nephrology : JASN.

[39]  M. Tso,et al.  Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. , 1985, Archives of ophthalmology.

[40]  D. Jones.  Membranoproliferative glomerulonephritis. One of many diesases? , 1977, Archives of pathology & laboratory medicine.

[41]  H. Lutz,et al.  Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. , 2004, Blood.

[42]  R. R. Robinson,et al.  Membranoproliferative glomerulonephritis with dense intramembranous alterations. A clinicopathologic study. , 1977, Laboratory investigation; a journal of technical methods and pathology.

[43]  P. Gallé,et al.  Electron dense alteration of kidney basement membranes. A renal lesion specific of a systemic disease. , 1975, The American journal of medicine.

[44]  D. Witte,et al.  Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  A. O. Muda,et al.  Ultrastructural histochemical investigations of “dense deposit disease”. Pathogenetic approach to a special type of mesangiocapillary glomerulonephritis , 2004, Virchows Archiv A.

[46]  J. H. Jansen,et al.  Eradication of porcine factor H deficiency in Norway , 1997, Veterinary Record.

[47]  A. Bernard,et al.  The clinical course associated with dense deposits in the kidney basement membranes , 1972 .

[48]  P. Zipfel,et al.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). , 2006, Kidney International.

[49]  S. Richards,et al.  Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.

[50]  John D Lambris,et al.  Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. , 2000, Immunopharmacology.

[51]  P. Rossmann,et al.  [Dense deposit nephropathy: a peculiar variant of glomerulonephritis or a distinct disease entity (author's transl)]. , 1975, Zentralblatt fur allgemeine Pathologie u. pathologische Anatomie.

[52]  A. Garg,et al.  Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature , 2004, Medicine.

[53]  A. J. Mcadams,et al.  Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): observations in six children. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  H. Colten,et al.  Human Factor H Deficiency , 1997, The Journal of Biological Chemistry.

[55]  P. Mathieson,et al.  Deficiency and depletion of complement in the pathogenesis of nephritis and vasculitis. , 1993, Kidney international. Supplement.

[56]  E. Schneeberger,et al.  Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children. , 1978, Clinical nephrology.

[57]  E. Ritz,et al.  The Nephrotic Syndrome , 1998 .

[58]  M. Little,et al.  Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. , 2006, Kidney international.

[59]  M. Gubler,et al.  Dense deposit disease: a variant of membranoproliferative glomerulonephritis. , 1975, Kidney international.

[60]  P. Gallé,et al.  Chemical properties of human glomerular basement membrane in the nephropathy with electron dense deposits inside the basement membrane. , 1976, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

[61]  M. Walport,et al.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.

[62]  J. Shortland,et al.  Renal disease in partial lipodystrophy. , 1972, The Quarterly journal of medicine.

[63]  P. Zipfel,et al.  Complement and diseases: defective alternative pathway control results in kidney and eye diseases. , 2006, Molecular immunology.

[64]  Glomerulonephritis recurrence in the renal graft. , 2001, Journal of the American Society of Nephrology : JASN.

[65]  B. Diamond,et al.  Autoimmune diseases , 2000, Bone Marrow Transplantation.

[66]  D. Stablein,et al.  Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. , 2005, Journal of the American Society of Nephrology : JASN.

[67]  S. Russell,et al.  Drusen associated with aging and age‐related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  G. Deschênes,et al.  Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. , 2004, Journal of the American Society of Nephrology : JASN.

[69]  J. Walshe,et al.  Response to ‘Differences between type I and II membranoproliferative glomerulonephritis’ , 2006 .

[70]  B. Spiegelman,et al.  Adipsin and complement factor D activity: an immune-related defect in obesity , 1989, Science.

[71]  C. Cronin,et al.  Lupus, C3 nephritic factor and partial lipodystrophy. , 1995, QJM : monthly journal of the Association of Physicians.

[72]  P. Lachmann,et al.  Complement-mediated adipocyte lysis by nephritic factor sera , 1993, The Journal of experimental medicine.

[73]  W. Bennett,et al.  Mesangiocapillary glomerulonephritis type II (dense-deposit disease): clinical features of progressive disease. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[74]  M. Daha,et al.  Complement and the kidney: what the nephrologist needs to know in 2006? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[75]  A. Schlueter,et al.  Management of membranoproliferative glomerulonephritis type II with plasmapheresis , 2002, Journal of clinical apheresis.

[76]  M. Nagata,et al.  Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation , 2006, Pathology international.

[77]  B. Burke,et al.  Dense intramembranous deposit disease: a clinical comparison of histological subtypes. , 1990, Clinical nephrology.

[78]  C. le Grimellec,et al.  Primary culture of rabbit proximal tubules as a cellular model to study nephrotoxicity of xenobiotics. , 1993, Kidney international.

[79]  N. Gretz,et al.  Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: A long‐term follow‐up , 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[80]  A. Michael,et al.  Immunofluorescence studies of dense deposit disease. The presence of railroad tracks and mesangial rings. , 1979, Laboratory investigation; a journal of technical methods and pathology.

[81]  J. Wetzels,et al.  Differences between type I and II membranoproliferative glomerulonephritis. , 2006, Kidney international.

[82]  Leibowitz,et al.  Transplantation in mesangiocapillary glomerulonephritis with intramembranous dense "deposits": recurrence of disease. , 1976, Kidney international.

[83]  J. H. Jansen,et al.  In situ complement activation in porcine membranoproliferative glomerulonephritis type II. , 1998, Kidney international.

[84]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[85]  D. Colville,et al.  Visual impairment caused by retinal abnormalities in mesangiocapillary (membranoproliferative) glomerulonephritis type II ("dense deposit disease"). , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[86]  J. H. Jansen,et al.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. , 1995, The Journal of clinical investigation.

[87]  J. H. Jansen,et al.  The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. , 2002, The American journal of pathology.

[88]  S. Bonsib,et al.  Dense deposit disease is not a membranoproliferative glomerulonephritis , 2007, Modern Pathology.

[89]  P Vivien,et al.  [The nephrotic syndrome]. , 1965, Le Progres medical.

[90]  C. Rance,et al.  Characteristics of a benign subtype of dense deposit disease: comparison with the progressive form of this disease. , 1983, Clinical nephrology.

[91]  D. Wilson,et al.  Mesangiocapillary glomerulonephritis with dense "deposits" in the basement membranes of the kidney. , 1976, Clinical nephrology.

[92]  N. McKechnie,et al.  Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. , 1989, The British journal of ophthalmology.

[93]  H. Cook,et al.  Complement and glomerulonephritis: new insights , 2005, Current opinion in nephrology and hypertension.

[94]  P. Thorner,et al.  Extraglomerular dense deposits in dense deposit disease. , 1982, Archives of pathology & laboratory medicine.

[95]  G. Remuzzi,et al.  Factor H family proteins: on complement, microbes and human diseases. , 2001, Biochemical Society transactions.

[96]  D. Isenberg,et al.  C3 nephritic factor and SLE: report of four cases and review of the literature. , 1994, QJM : monthly journal of the Association of Physicians.

[97]  J L McRae,et al.  Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease) , 2005, Journal of Medical Genetics.

[98]  J. Thurman,et al.  The Central Role of the Alternative Complement Pathway in Human Disease1 , 2006, The Journal of Immunology.

[99]  S. Rodríguez de Córdoba,et al.  The human complement factor H: functional roles, genetic variations and disease associations. , 2004, Molecular immunology.

[100]  M. Kazatchkine,et al.  Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[101]  R. Habib,et al.  The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases. , 1971, Pathology annual.